|
|
|
|
| |
|
GENERIC HYPERTENSION DRUG |
Ranbaxy gets conditional nod to
sell Norvasc generic pills in US
June 25, 2007
The US arm of India’s top drug maker Ranbaxy
Laboratories received tentative approval to sell
low cost versions of anti-hypertension drug
amlodipine in the United States.
Its wholly owned subsidiary Ranbaxy
Pharmaceuticals Inc. announced that the company
has been granted conditional okay by the US Food
and Drug Administration to manufacture and market
amlodipine besylate tablets in 2.5 mg, 5 mg and 10
mg strengths.
Currently sold by the world’s leading drug firm
Pfizer, in the proprietary name Norvasc, sales of
amlodipine besylate tablets touched US $2.79
billion in the year 2007, according to IMS
figures.
Apart from hypertension amlodipine is also
indicated for the symptomatic treatment of chronic
stable angina and may be used alone or in
combination with other antianginal agents. The
product is also indicated for the treatment of
confirmed or suspected vasospastic angina and may
be used as monotherapy or in combination with
other antianginal drugs.
This product represented a future opportunity for
Ranbaxy and would be launched following final
approval from the FDA. This product would further
expand the company’s product portfolio of
affordable generic alternatives, said Jim Meehan,
Vice President of Sales and Marketing for RPI in
an official statement.
Ranbaxy Pharmaceuticals Inc. (RPI) based in
Jacksonville, Florida, is a wholly owned
subsidiary of Ranbaxy Laboratories Limited (RLL),
India’s largest pharmaceutical company. RPI is
engaged in the sale and distribution of generic
and branded prescription products in the U.S.
healthcare system.
Headquartered in Gurgaon, India, Ranbaxy
Laboratories Limited, is an integrated, research
based, international pharmaceutical company
producing a wide range of quality, affordable
generic medicines, trusted by healthcare
professionals and patients across geographies.
Ranbaxy’s continued focus on R&D has resulted in
several approvals in developed markets and
significant progress in New Drug Discovery
Research. The Company’s foray into Novel Drug
Delivery Systems has led to proprietary "platform
technologies", resulting in a number of products
under development. The Company is serving its
customers in over 125 countries and has an
expanding international portfolio of affiliates,
joint ventures and alliances, ground operations in
49 countries and manufacturing operations in 11
countries.
|
|
|
